To explore the mechanism of actions underlying the tested compounds anti-diabetic neuropathy activities, the levels of the in vivo antioxidants (CAT, GSH, and LPO) serum levels were monitored for various diabetic-neuropathy groups prior to and 8 weeks post test compounds administration (Table 5). This evidence concerns the gene LPO and diabetes mellitus.